JAY W. MARKS, M.D.; RICHARD A. BAUM, M.D.; RUSSELL F. HANSON, M.D.; THEODORE HERSH, M.D.; N. C. HIGHTOWER, M.D.; HAGOP MEKHJIAN, M.D.; ROBERT A. SCHAEFER, M.D.; ROGER D. SOLOWAY, M.D.; JOHNSON L. THISTLE, M.D.; FRED B. THOMAS, M.D.; MALCOLM P. TYOR, M.D.
MARKS JW, BAUM RA, HANSON RF, HERSH T, HIGHTOWER NC, MEKHJIAN H, et al. Additional Chenodiol Therapy After Partial Dissolution of Gallstones with Two Years of Treatment. Ann Intern Med. 1984;100:382-384. doi: 10.7326/0003-4819-100-3-382
Download citation file:
Published: Ann Intern Med. 1984;100(3):382-384.
During the National Cooperative Gallstone Study, therapy with chenodiol, 750 or 375 mg/d, for 2 years resulted in confirmed, complete gallstone dissolution in 14% and 5% of patients, respectively, and partial dissolution (> 50%) in 27% and 18%. The present study was done to determine the frequency with which complete dissolution occurs in patients having partial dissolution of gallstones who receive additional therapy. Eighty-six of one hundred thirty-eight eligible patients continued to receive 750 mg/d (61 patients) or 375 mg/d (25 patients) of chenodiol for 1 year. Patients whose oral cholecystogram at the end of the year showed further (> 50%) dissolution continued to receive chenodiol (28 patients at 750 mg/d and 11 patients at 375 mg/d) for a second year (total duration of therapy, 4 years). A final oral cholecystogram was taken at the end of the fourth year. Complete dissolution occurred in 23% and 16% of patients receiving chenodiol, 750 or 375 mg/d, respectively, for an additional 1 or 2 years.
Learn more about subscription options.
Register Now for a free account.
Biliary Disorders, Gastroenterology/Hepatology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only